FDA Approved: FLUDEOXYGLUCOSE F18 — Supplemental Application (THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH)

View source ↗

Summary

FDA has approved a supplemental application for Fludeoxyglucose F-18, a PET radiopharmaceutical, reflecting an update to its labeling and/or scope of use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Cardiovascular Disease
• Neurodegenerative Diseases

Drugs mentioned

• Fludeoxyglucose F-18 (Fludeoxyglucose F-18)

Snippet

SUPPL AP for FLUDEOXYGLUCOSE F18 (FLUDEOXYGLUCOSE F18)